SHR-1918
Monoclonal antibody
Evidence outlook · regulatory review
Homozygous Familial Hypercholesterolemia: application under NMPA review
NMPA accepts the SHR-1918 marketing application in HoFH, with priority review (2026-02-24). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
NCT06723652: This is a randomized, quadruple-blinded, placebo-controlled trial with a disease-defining efficacy endpoint (percent change in LDL cholesterol), but results have not been posted, so whether SHR-1918 lowered LDL cholesterol significantly versus placebo cannot yet be confirmed from this record.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06723652 NCT06723652 · Homozygous Familial Hypercholesterolemia This is a randomized, quadruple-blinded, placebo-controlled trial with a disease-defining efficacy endpoint (percent change in LDL cholesterol), but results have not been posted, so whether SHR-1918 lowered LDL cholesterol significantly versus placebo cannot yet be confirmed from this record. Registry: NCT06723652 | 3 | Percent change in calculated LDL-C from baseline to week 12 2025-08-25 | LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 | Partial signal | link ↗ |
View 1 more trial
NCT06009393 NCT06009393 · Homozygous Familial Hypercholesterolemia Registry: NCT06009393 | 2 | Percent change in calculated LDL-C from baseline to week 12 2024-06-29 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
Other ANGPTL3 drugs
Evinacumab, ALN-ANG3, BW-00112, EDP167, Solbinsiran and 3 more. Compare all 9 ANGPTL3 drugs
This mechanism is crowded: 9 other tracked programmes target it, 1 of them ahead of this one.
This drug's own stage for Homozygous Familial Hypercholesterolemia: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-1918: this drug | Phase 3 | Monoclonal antibody | ANGPTL3 | Partial signal | NCT06723652: LDL-C -58.8% vs +5.5% with placebo at week 12 (difference -64.2%), ESC 2026 | |
| Alirocumab (Praluent) | Approved | Monoclonal antibody | PCSK9 | Partial signal | NCT03156621: Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 12 (Intent-to-Treat [ITT] Estimand) (Baseline to Week 12): Alirocumab 150 mg SC Q2W -26.9 Percentage of change (Standard Error 4.6) vs Placebo in DBTP 8.6 Percentage of change (Standard Error 6.3) | |
| Evinacumab (Evkeeza) | Approved | Monoclonal antibody | ANGPTL3 | Partial signal | NCT03399786: Percent Change in Calculated Low-Density Lipoprotein Cholesterol (LDL-C) From Baseline to Week 24 (Intent-to-Treat [ITT] Estimand) (Week 24): Evinacumab 15 mg/kg IV Q4W -47.1% (Standard Error 4.6) vs Placebo IV Q4W 1.9% (Standard Error 6.5) | |
| Evolocumab (Repatha) | Approved | Monoclonal antibody | PCSK9 | Reliable signal | NCT01588496: Part B: Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12: Evolocumab -23.05% (Standard Error 3.78) vs Placebo 7.88% (Standard Error 5.26); LS mean treatment difference -30.93% (95% CI -43.86 to -18.00), p<0.001 | |
| Ezetimibe (Zetia) | Approved | Small molecule | Dietary Cholesterol Absorption Inhibitor, NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Ezetimibe / Simvastatin (Vytorin) | Approved | Small molecule | HMG-CoA reductase / NPC1L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Inclisiran (Leqvio) | Approved | RNA / oligonucleotide | PCSK9 | Partial signal | NCT04659863: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) (Baseline and Day 330): Part 1- Inclisiran -21.6% (Standard Deviation 13.36) vs Part 1 - Placebo 11.7% (Standard Deviation 30.52) | |
| Lomitapide (Juxtapid) | Approved | Small molecule | MTP | Weak signal | NCT04681170: Efficacy Endpoint: Percent Change in Low-density Lipoprotein Cholesterol (LDL C) at Week 24 Compared to Baseline (Baseline through Week 24): Age 5-10 Years -56.529% (Standard Deviation 26.5401) | Age 11-17 Years -51.633% (Standard Deviation 25.5658) NCT02173158: Percent Change in LDL-C (Baseline to Week 26): Lomitapide -42.2% (Standard Deviation 18.16) | |
| Rosuvastatin | Approved | Small molecule | HMG-CoA reductase | not yet graded | No reviewed efficacy summary in this indication | |
| Zodasiran | Phase 3 | RNA / oligonucleotide | ANGPTL3 gene mRNA (hepatic) | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-ANG3 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BW-00112 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| EDP167 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Solbinsiran | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SYH2070 | Phase 2(overall) | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CTX310 | Phase 1(overall) | Gene therapy / editing | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| NNC0491-6075 | Phase 1(overall) | Monoclonal antibody | ANGPTL3 | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| AZD1705 | Discontinued | RNA / oligonucleotide | ANGPTL3 | not yet graded(overall) | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow SHR-1918 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
March 2027 (1)
What to watch
June 2027 (1)
What to watch
October 2027 (1)
What to watch
2028 (1)
July 2028 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent